CRWV Form 144 Filed — Insider Plans Sale of 14,615 Shares on NASDAQ
Rhea-AI Filing Summary
CoreWeave, Inc. (CRWV) Form 144 — An authorized sale notice reports an intended sale of 14,615 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,000,062.75, and an approximate sale date of 10/01/2025 on NASDAQ. The shares were acquired as Founders Shares on 12/27/2023. The filing shows total outstanding shares of 370,470,348, placing the planned sale at a small fraction of outstanding stock. The document also lists multiple recent sales by related parties and entities during August–September 2025, including several 10b5-1 plan transactions and substantial gross proceeds reported.
Positive
- Transparency: The filing discloses the broker (Morgan Stanley Smith Barney LLC), acquisition date (12/27/2023), and nature of the shares (Founders Shares).
- Rule 10b5-1 usage disclosed: Multiple prior sales are clearly labeled as 10b5-1 plan transactions, indicating planned, pre-arranged dispositions.
Negative
- Insider/affiliate selling activity: Several large sales during Aug–Sep 2025 produced substantial gross proceeds, which could raise investor attention about insider liquidity.
- Concentration of prior sales: Multiple sizable disposals by related parties (e.g., West Clay Capital LLC) in a short period are reported.
Insights
TL;DR Insider sale notice for 14,615 shares valued at ~$2.0M; prior 10b5-1 sales indicate ongoing disposition activity.
The Form 144 notifies the SEC and market that an insider or restricted holder intends to sell 14,615 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $2,000,062.75 and an approximate sale date of October 1, 2025. The shares were acquired as founders shares on December 27, 2023. The filing also discloses several sizable sales by related parties and trusts during August and September 2025, many labelled as 10b5-1 plan sales, producing multi-million dollar gross proceeds. For investors, this is a routine disclosure of planned insider sales rather than operational or financial performance information.
TL;DR Disclosure is compliant and details both the proposed sale and recent affiliated 10b5-1 transactions.
The submission provides required detail on the nature and origin of the shares (founders shares acquired 12/27/2023) and identifies the broker and intended exchange. It also lists multiple prior dispositions by individuals and entities, notably several 10b5-1 plan sales with significant gross proceeds in August–September 2025. This supports transparency about insider liquidity events and adherence to rule-based sale plans. The document contains the standard representation that the seller is not aware of undisclosed material adverse information.